Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R43/R44 Clinical Trials Not Allowed)

The purpose of this funding opportunity is to develop artificial intelligence tools and experimental assays to identify new pharmacotherapeutics with lower toxicity and higher efficacy for substance use disorders (SUD) Areas of interest include but are not limited to: 1) Development of AI tools to identify potential target combinations, design new molecules, conduct virtual preclinical studies to predict efficacy and toxicity, and model in vitro and in vivo polypharmacology 2) Development of assays to assess the effects of compounds on multiple targets or functions